RESUMO
BACKGROUND: Type 2 diabetes (T2D) is influenced by diverse environmental and genetic risk factors. Metabolic syndrome (MS) increases the risk of cardiovascular disease and diabetes. We analysed 14 cases of polymorphisms located in 10 candidate loci, in a sample of patients with T2D and controls from Mexico City. METHODS: We analysed the association of 14 polymorphisms located within 10 genes (TCF7L2, ENPP1, ADRB3, KCNJ11, LEPR, PPARgamma, FTO, CDKAL1, SIRT1 and HHEX) with T2D and MS. The analysis included 519 subjects with T2D defined according to the ADA criteria, 389 with MS defined according to the AHA/NHLBI criteria and 547 controls. Association was tested with the program ADMIXMAP including individual ancestry, age, sex, education and in some cases body mass index (BMI), in a logistic regression model. RESULTS: The two markers located within the TCF7L2 gene showed strong associations with T2D (rs7903146, T allele, odd ratio (OR) = 1.76, p = 0.001 and rs12255372, T allele, OR = 1.78, p = 0.002), but did not show significant association with MS. The non-synonymous rs4994 polymorphism of the ADRB3 gene was associated with T2D (Trp allele, OR = 0.62, p = 0.001) and MS (Trp allele, OR = 0.74, p = 0.018). Nominally significant associations were also observed between T2D and the SIRT1 rs3758391 SNP and MS and the HHEX rs5015480 polymorphism. CONCLUSIONS: Variants located within the gene TCF7L2 are strongly associated with T2D but not with MS, providing support to previous evidence indicating that polymorphisms at the TCF7L2 gene increase T2D risk. In contrast, the non-synonymous ADRB3 rs4994 polymorphism is associated with T2D and MS.
Assuntos
Diabetes Mellitus Tipo 2/genética , Síndrome Metabólica/genética , Polimorfismo Genético , Adulto , Fatores Etários , Glicemia/metabolismo , Pressão Sanguínea/genética , Índice de Massa Corporal , Peso Corporal/genética , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Diabetes Mellitus Tipo 2/etnologia , Escolaridade , Feminino , Estudos de Associação Genética , Humanos , Insulina/sangue , Resistência à Insulina/genética , Masculino , Síndrome Metabólica/etnologia , México , Pessoa de Meia-Idade , Triglicerídeos/sangueRESUMO
Adult patients with chronic autoimmune thrombocytopenic purpura (ATP), which proved refractory to various treatments, received a single dose of autologous in vitro opsonized erythrocytes with 100 micrograms of anti-D IgG. In 1983, 30 of these patients were treated with autologous erythrocytes that had been opsonized and labeled with 25 mCi (740 MBq) of technetium Tc 99m; this treatment was designated as the radioimmune method. Favorable responses were noted in 36% of patients so treated. In 1985, another group of 16 patients with refractory ATP received therapy with autologous opsonized erythrocytes (AOPE) and 55% of these patients showed favorable responses. Five (17%) of the patients treated using the radioimmune method attained a complete, long-term (greater than 35 months) remission of their ATP, and five (31%) of the patients treated using AOPE remained in complete remission over 270 days after cessation of therapy. Major complications were not seen. We concluded that the interaction of macrophages with low-dose AOPE is a successful therapeutic approach in ATP refractory to standard treatment.
Assuntos
Doenças Autoimunes/terapia , Eritrócitos , Imunização Passiva , Proteínas Opsonizantes , Púrpura Trombocitopênica/terapia , Tecnécio/uso terapêutico , Adolescente , Adulto , Idoso , Doenças Autoimunes/sangue , Doenças Autoimunes/tratamento farmacológico , Resistência a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Contagem de Plaquetas , Púrpura Trombocitopênica/sangue , Púrpura Trombocitopênica/tratamento farmacológico , Imunoglobulina rho(D)RESUMO
A case with evidence of acquired von Willebrand's syndrome associated with systemic lupus erythmatosus and Sjögren's syndrome is described. The patient, who had no family history of bleeding, presented a haemorrhagic diathesis of recent origin, the bleeding time was prolonged, procoagulant Factor-VIII and von Willebrand factor levels were low and platelet aggregation was decreased with different concentrations of Ristocetin. No improvement was seen after the tranfusion of cryoprecipitates, and there was no increase in procoagulant Factor-VIII. Clinical improvement resulted after treatment with corticosteroids, and later, the laboratory abnormalities characteristic of von Willebrand's disease became normal. The level of procoagulant factor-VIII reached the very high level of 810%.
Assuntos
Doenças Autoimunes/sangue , Doenças de von Willebrand/sangue , Adulto , Testes de Coagulação Sanguínea , Transfusão de Sangue , Feminino , Humanos , Hidrocortisona/uso terapêutico , Tempo de Tromboplastina Parcial , Agregação Plaquetária , Testes de Função Plaquetária , Síndrome , Doenças de von Willebrand/terapiaRESUMO
Germline mutations in patients with hemophilia B generally have arisen within the past 150 years. Evidence suggests that these germline mutations generally result from endogenous processes. However, a unique pattern would be expected if a population were exposed to a physiologically important germline mutagen since mutagens generally produce characteristic patterns, or "fingerprints", of mutation. To determine the pattern of mutation in Mexican Hispanics, the regions of likely functional significance in the factor IX gene were screened by dideoxy fingerprinting (ddF) in 31 families with hemophilia B. Mutations were found in 30 of these families. Haplotype analysis was performed on individuals with identical mutations to help distinguish independent, recurrent mutations from founder effects. Analysis of these 30 mutations, along with 7 mutations reported previously in Mexican Hispanic families, reveals a pattern of independent mutation that is similar to the pattern of mutation observed in 127 U.S. Caucasian families (p = 0.89). These results may reflect either an underlying pattern of germline mutation due to endogenous processes or the presence of an ubiquitous mutagen. Further analyses of the recurrent mutations revealed that two mutations, T296M and R248Q, accounted for 19% of the mutations found in the Mexicans. Haplotype data suggest that the multiple occurrences of T296M and R248Q are associated with founder effects and that screening for these mutations may allow rapid mutation detection and carrier diagnosis in a significant minority of Mexican families with hemophilia B, These two mutations also are associated with founder effects in the U.S, Caucasian population. However, the haplotypes are different in these two populations, indicating independent origins. The occurrence of identical founder mutations in distinct populations provides evidence for the previous hypothesis that the number of different mutations giving rise to mild or borderline mild/moderate hemophilia B is small compared to deleterious mutations causing more severe disease.
Assuntos
Fator IX/genética , Efeito Fundador , Mutação em Linhagem Germinativa , Hemofilia B/genética , Feminino , Haplótipos , Hemofilia B/epidemiologia , Humanos , Masculino , México/epidemiologia , Estados Unidos/epidemiologia , População Branca/genéticaRESUMO
Six patients with acute lymphoblastic leukemia manifested liver dysfunction related to doxorubicin hydrochloride therapy. Other causes, eg, infection, hepatitis, posttransfusion reaction, and leukemic infiltration were ruled out. There was close correlation between the administration of doxorubicin and the appearance of hepatic dysfunction. Doxorubicin may produce an idiosyncratic reaction and must be considered a drug with potential liver toxicity.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/etiologia , Doxorrubicina/efeitos adversos , Adolescente , Adulto , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Doença Hepática Induzida por Substâncias e Drogas/sangue , Doença Hepática Induzida por Substâncias e Drogas/patologia , Feminino , Humanos , Testes de Função Hepática , Masculino , NecroseAssuntos
Líquido Ascítico , Coagulação Intravascular Disseminada/etiologia , Infusões Parenterais/efeitos adversos , Líquido Ascítico/análise , Fatores de Coagulação Sanguínea/análise , Humanos , Cirrose Hepática/complicações , Tempo de Tromboplastina Parcial , Derivação Peritoneovenosa/efeitos adversos , UltrafiltraçãoAssuntos
Agranulocitose/induzido quimicamente , Cimetidina/efeitos adversos , Guanidinas/efeitos adversos , Neutropenia/induzido quimicamente , Bradicardia/induzido quimicamente , Úlcera Duodenal/complicações , Úlcera Duodenal/tratamento farmacológico , Hemofilia A/complicações , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Prednisona/administração & dosagem , Púrpura Trombocitopênica/terapia , Esplenectomia , Adolescente , Adulto , Idoso , Azatioprina/administração & dosagem , Criança , Ciclofosfamida/administração & dosagem , Feminino , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Fatores de TempoAssuntos
Mielofibrose Primária/diagnóstico , Adulto , Idoso , Anemia Mielopática/complicações , Transfusão de Sangue , Medula Óssea/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mielofibrose Primária/complicações , Mielofibrose Primária/patologia , Esplenectomia , Esplenomegalia/complicaçõesAssuntos
Complexo Ferro-Dextran/efeitos adversos , Adulto , Idoso , Anemia Hipocrômica/tratamento farmacológico , Artrite/induzido quimicamente , Infecções Bacterianas/etiologia , Feminino , Humanos , Infusões Parenterais , Complexo Ferro-Dextran/administração & dosagem , Complexo Ferro-Dextran/uso terapêutico , Masculino , Pessoa de Meia-IdadeAssuntos
Leucemia Linfoide/tratamento farmacológico , Prednisolona/uso terapêutico , Vincristina/uso terapêutico , Doença Aguda , Adulto , Medula Óssea/efeitos dos fármacos , Ensaios Clínicos como Assunto , Avaliação de Medicamentos , Feminino , Hematopoese/efeitos dos fármacos , Humanos , MasculinoAssuntos
Hematologia/tendências , Hemofilia A/terapia , Humanos , Leucemia/terapia , Linfoma/terapia , Trombose/terapiaRESUMO
In order to analyze the usefulness of different types of treatment in relation to the interval since the onset of idiopathic thrombocytopenic purpura (ITP), a collaborative study of 934 adult patients was undertaken. Prednisone was administered to 818 patients, and 32% of them achieved prolonged complete remission (PCR). However, only 14% of patients who had ITP for more than six months achieved a prednisone-induced PCR (P less than .01). Splenectomy was done in 399 patients, and 65% of them achieved PCR; the remission rate did not vary with the interval since the onset of ITP. Of 120 patients with chronic ITP that was refractory to corticosteroids and splenectomy, 91 received either azathioprine or cyclophosphamide; 21% of them achieved PCR and 55% had a favorable response. None of 19 patients treated with vincristine and only one of ten patients treated with vinblastine-loaded platelets achieved PCR.
Assuntos
Imunossupressores/uso terapêutico , Púrpura Trombocitopênica/terapia , Adolescente , Corticosteroides/uso terapêutico , Adulto , Idoso , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Púrpura Trombocitopênica/mortalidade , Esplenectomia , Vimblastina/uso terapêutico , Vincristina/uso terapêuticoRESUMO
A functionally normal but structurally abnormal prothrombin variant was found in a Mexican family. Immunoisoelectricfocusing studies revealed that this variant has a more acidic isoelectric point (4.01) than normal prothrombin (4.29), but it proved to have a normal molecular weight as assessed by sodium-dodecyl-sulphate polyacrylamide gel electrophoresis. Two-dimensional immunoelectrophoresis studies showed an abnormal cleavage of the prothrombin molecule by factor Xa and Echis carinatus venom as well, despite the fact that both yield functionally normal thrombin molecules. Finally, the ability of the molecule to bind calcium ions as well as its overall antigenic structure were investigated and found to be normal. These results taken together suggest a simple (substitution or translocation) mutation at the fragment 2 level. Since this prothrombin variant is different from others described previously, the name "Mexico City" is proposed to identify it.
Assuntos
Protrombina/genética , Adulto , Aberrações Cromossômicas/genética , Transtornos Cromossômicos , Feminino , Genes Dominantes , Variação Genética , Humanos , Imunoeletroforese Bidimensional , Masculino , México , Linhagem , Conformação Proteica , Protrombina/análiseRESUMO
Idiopathic thrombocytopenic purpura (ITP) is more frequently seen in young females than in any other age or sex group. Danazol, an impeded androgen with a decreased masculinizing potential, has been described as useful in ITP. A total of 25 women 16 to 41 years of age, with chronic ITP were studied. All patients were refractory to treatments with glucocorticoids and splenectomy; 19 were inadequately controlled by immunosuppressants, vinblastine or vincristine-loaded platelets, the radioimmune method, colchicine, plasmapheresis, or surgery for accessory spleens. Danazol was given at a daily dosage of 600 mg for 4 months. All showed clinical improvement, as indicated by cessation or decrease of bleeding, and 12 (48%) cases obtained a drug-dependent excellent or good response of their ITP. Therapy produced amenorrhea or oligomenorrhea in 21 patients (84%) and 7 cases of chronic metrorrhagia were successfully controlled. The drug was well tolerated. Accordingly, danazol may be an effective treatment for ITP or related conditions, especially in adult females with uncontrollable metrorrhagia.
Assuntos
Danazol/uso terapêutico , Metrorragia/tratamento farmacológico , Pregnadienos/uso terapêutico , Púrpura Trombocitopênica/tratamento farmacológico , Adolescente , Adulto , Amenorreia/induzido quimicamente , Danazol/efeitos adversos , Feminino , Humanos , Metrorragia/etiologia , Oligomenorreia/induzido quimicamente , Prednisona/uso terapêutico , Púrpura Trombocitopênica/complicaçõesRESUMO
At the present time, it is possible to achieve up to a 95% complete remission in childhood acute lymphoblastic leukemia, using the combination of vincristine and prednisone. Nevertheless, it has not been possible to reproduce these results in the adult. For this reason, a third drug, in this case adriamycin in a low dose, was added to the vincristine-prednisone combination in the treatment of adult acute lymphoblastic leukemia (ALL). Complete remission was achieved in 45 of the 50 patients (90%). The median duration of remission was 23 months and the median survival time in this group was 31 months. The complications were minimal and the tolerance was good. From the point of view of our results and others reported in the literature, we consider that the combination of vincristine, prednisone, and adriamycin is a useful method for induction of remission of adult ALL.
Assuntos
Doxorrubicina/administração & dosagem , Leucemia Linfoide/tratamento farmacológico , Prednisona/uso terapêutico , Vincristina/uso terapêutico , Adolescente , Adulto , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Fatores de TempoRESUMO
We evaluated the use of heparin in continuous flow centrifugation by continuous infusion. Doses were modified by assessment of the anticoagulant effect by the thrombin time dilution test (TTDT). Heparin is an efficient anticoagulant in continuous flow centrifugation and the TTDT is an effective and reliable method for control. The initial dose in leukapheresis is one unit per milliliter of blood during the first hour, then one-half the dose during the next hour, and then a one-quarter of the dose until the procedure is completed. A TTDT performed every 30 to 60 minutes will indicate whether the heparin dose should be modified. For plasmapheresis, it is necessary to determine the specific dose for each patient. There was no case of bleeding or extracorporeal coagulation of the blood.